HLB파나진

046210KOSDAQ의료용품 및 기타 의약 관련제품 제조업

58.6 / 100

Reference Date: 2026-07-24

Financial Score22.0 / 40

News Sentiment19.6 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Plunged 25.9% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Panajin is a specialized biotech venture company focusing on PNA (Peptide Nucleic Acid)-based bio materials and molecular diagnostics. The company develops and commercializes diverse diagnostic products, including somatic mutation detection, liquid biopsy, and automated diagnostic technologies, leveraging its PNA platform. Its subsidiary, BioSquare, expands into immunoassay technologies, while the company aims to build an AI-based diagnostic platform and develop PNA-based therapeutics for comprehensive healthcare solutions.

Number of Employees

84people

Average Salary

51.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.184.0Point

PBR

0.67Industry Average 1.095.5Point

Lower than industry avg (good)

ROE

-4.21Industry Average -4.893.5Point

Below industry avg

Debt Ratio

2.48Industry Average 6.866.5Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼63.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -5.8% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 1Neutral 0Negative 2Average Sentiment Score 78.3

Positive
HLB 그룹株, '리보세라닙' FDA 불발 사유 해소에 무더기 '上'
HLB파나진의 간암 신약 리보세라닙 FDA 허가 문제 해결로 주가가 급등했다.
Negative
[특징주] HLB그룹주, FDA 승인 무산에 줄줄이 ‘하한가’
HLB파나진 주가가 FDA 승인 무산으로 인해 하한가로 급락했다.
Negative
FDA서 세 번째 보완요구서 수령…HLB그룹株 '무더기 하한가'
HLB파나진 주가가 FDA의 세 번째 보완요구서 수령 소식으로 인해 급락했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,061Won52-week high 2,65052-week low 1,061

1-month return0.0Point

1m -25.91% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-22
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-16
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-16
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-30
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-30